Vera Therapeutics (VERA) had the highest return in January 2024 by a mid-cap US stock, returning 139.6%.

ASSET	MONTH	% RETURN
Vera Therapeutics (VERA)	January 2024	139.61%
Trump Media & Technology (DJT)	January 2024	115.14%
Dave (DAVE)	January 2024	112.39%
Arcutis Biotherapeutics (ARQT)	January 2024	85.17%
Dianthus Therapeutics (DNTH)	January 2024	84.81%
NewAmsterdam Pharma Company NV Ordinary Shares (NAMS)	January 2024	82.77%
Sezzle (SEZL)	January 2024	80.91%
Dyne Therapeutics (DYN)	January 2024	64.36%
Edgewise Therapeutics (EWTX)	January 2024	63.13%
Immunome (IMNM)	January 2024	53.43%
Establishment Labs (ESTA)	January 2024	51.04%
ZIM Integrated Shipping Services (ZIM)	January 2024	44.23%
Intuitive Machines (LUNR)	January 2024	43.73%
Axogen (AXGN)	January 2024	43.05%
GeneDx (WGS)	January 2024	42.59%
Oscar Health (OSCR)	January 2024	38.65%
Tarsus Pharmaceuticals (TARS)	January 2024	36.2%
Powell Industries (POWL)	January 2024	36.15%
Kodiak Sciences (KOD)	January 2024	34.11%
Viking Therapeutics (VKTX)	January 2024	30.28%
Almonty Industries Inc Common Shares (ALM)	January 2024	29.66%
Innodata (INOD)	January 2024	29.63%
GH Research (GHRS)	January 2024	29.3%
Kymera Therapeutics (KYMR)	January 2024	28.65%
Mineralys Therapeutics, Inc Common Stock (MLYS)	January 2024	28.5%

Mid-cap stocks are treated as having a market cap between $2B and $10B.